Literature DB >> 11568571

Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands.

M D Gibbons1, U Manne, W R Carroll, G E Peters, H L Weiss, W E Grizzle.   

Abstract

OBJECTIVE/HYPOTHESIS: Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC), the most common malignancies of the major salivary glands, are clinically and pathologically different. To determine whether MEC and ACC have different molecular characteristics, we examined the expression of erbB-2, erbB-3, epidermal growth factor receptor (EGFR), and transforming growth factor-alpha (TGF-alpha), important molecular features in other malignancies. STUDY DESIGN/
METHODS: Archival tissue sections of 22 MEC and 6 ACC tumors of the major salivary glands were evaluated immunohistochemically for expression of erbB-2, erbB-3, EGRF, and TGF-alpha. A differential immunostaining score, reflecting the difference in immunostaining between carcinoma and uninvolved salivary gland tissue, was calculated for cytoplasmic and membranous staining.
RESULTS: Positive immunostaining for all biomarkers was observed in the cytoplasm and membrane of both tumors. However, expression was higher in MEC than in ACC tumors and was statistically significant for cytoplasmic EGFR (P =.009), TGF-alpha (P =.041), and membranous EGFR (P =.004). A significantly higher percentage of MEC cells also demonstrated positive immunostaining for cytoplasmic erbB-3 (P =.022), EGFR (P =.005), membranous erbB-3 (P =.022), and EGFR (P =.013). The differential immunostaining score was significantly higher for MEC compared with uninvolved alveolar tissue and the membranes of uninvolved ductal tissue. There were no statistically positive differential immunostaining scores for ACC.
CONCLUSIONS: There is a clear difference in the molecular phenotypes of MEC and ACC. The lack of statistically significant expression in ACC, when compared with similar uninvolved salivary gland tissue, suggests minimal involvement for these molecular structures in the pathogenesis of ACC. Conversely, erbB-2, erbB-3, EGFR, and TGF-alpha may have a role in the development and progression of MEC. These results have therapeutic implications for MEC of the major salivary glands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568571     DOI: 10.1097/00005537-200108000-00011

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  18 in total

1.  Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade.

Authors:  D Milanovic; B Jeremic; G Kayser; H C Rischke; J Pfeiffer; A Henke
Journal:  Strahlenther Onkol       Date:  2012-04-12       Impact factor: 3.621

Review 2.  Beyond Surgical Treatment in Adenoid Cystic Carcinoma of the Head and Neck: A Literature Review.

Authors:  Sarah Atallah; Morgane Marc; Antoine Schernberg; Florence Huguet; Isabelle Wagner; Antti Mäkitie; Bertrand Baujat
Journal:  Cancer Manag Res       Date:  2022-06-04       Impact factor: 3.602

3.  Phase II study of gefitinib in patients with advanced salivary gland cancers.

Authors:  John A Jakob; Merrill S Kies; Bonnie S Glisson; Michael E Kupferman; Diane D Liu; J Jack Lee; Adel K El-Naggar; Ana M Gonzalez-Angulo; George R Blumenschein
Journal:  Head Neck       Date:  2015-03-30       Impact factor: 3.147

4.  Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors.

Authors:  Nikolaos G Nikitakis; Mark A Scheper; Vasileios S Papanikolaou; Alexandra Sklavounou; John J Sauk
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03-09

5.  Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.

Authors:  Ricardo S Macarenco; Timothy S Uphoff; Heather Flynn Gilmer; Robert B Jenkins; Stephen N Thibodeau; Jean E Lewis; Julian R Molina; Ping Yang; Marie-Christine Aubry
Journal:  Mod Pathol       Date:  2008-06-27       Impact factor: 7.842

Review 6.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

7.  Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands.

Authors:  B Lujan; S Hakim; S Moyano; A Nadal; M Caballero; A Diaz; A Valera; M Carrera; A Cardesa; L Alos
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 9.  Salivary gland neoplasms.

Authors:  Terry A Day; John Deveikis; M Boyd Gillespie; John K Joe; Besim Ogretmen; J David Osguthorpe; Susan G Reed; Mary S Richardson; Michael Rossi; Ranjiv Saini; Anand K Sharma; Robert K Stuart
Journal:  Curr Treat Options Oncol       Date:  2004-02

10.  Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.

Authors:  Salvatore Grisanti; Vito Amoroso; Michela Buglione; Anna Rosati; Roberto Gatta; Claudio Pizzocaro; Vittorio D Ferrari; Giovanni Marini
Journal:  J Med Case Rep       Date:  2008-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.